Investigation of miRNA Biology by Bioinformatic Tools and Impact of miRNAs in Colorectal Cancer—Regulatory Relationship of c-Myc and p53 with miRNAs by Xi, Yaguang et al.
Cancer Informatics 2007:3 245–253 245
REVIEW
Correspondence: Jingfang Ju, Ph.D., Cancer Genomics Laboratory, Mitchell Cancer Institute-USA, Mobile, 
AL 36688. Tel: (251) 460-7393; Fax: (251) 460-6994; Email: jju@usouthal.edu
Please note that this article may not be used for commercial purposes. For further information please refer to the  copyright 
statement at http://www.la-press.com/copyright.htm
Investigation of miRNA Biology by Bioinformatic Tools 
and Impact of miRNAs in Colorectal Cancer—Regulatory 
Relationship of c-Myc and p53 with miRNAs
Yaguang Xi,
1 John R. Edwards
2 and Jingfang Ju
1
1Cancer Genomics Laboratory, Mitchell Cancer Institute, University of South Alabama, Mobile, 
AL 36688, USA. 
2Laboratory of DNA Sequencing and Chemical Biology, Columbia Genome Center, 
Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Abstract: MicroRNAs (miRNAs) are a class of small non-coding RNAs that mediate gene expression at the post-
transcriptional and translational levels and have been demonstrated to be involved in diverse biological functions. Mounting 
evidence in recent years has shown that miRNAs play key roles in tumorigenesis due to abnormal expression of and muta-
tions in miRNAs. High throughput miRNA expression proﬁ  ling of several major tumor types has identiﬁ  ed miRNAs as-
sociated with clinical diagnosis and prognosis of cancer treatment. Previously our group has discovered a novel regulatory 
relationship between tumor suppressor gene p53 with miRNAs expression and a number of miRNA promoters contain 
putative p53 binding sites. In addition, others have reported that c-myc can mediate a large number of miRNAs expression. 
In this review, we will emphasize algorithms to identify mRNA targets of miRNAs and the roles of miRNAs in colorectal 
cancer. In particular, we will discuss a novel regulatory relationship of miRNAs with tumor suppressor p53 and c-myc. 
miRNAs are becoming promising novel targets and biomarkers for future cancer therapeutic development and clinical 
molecular diagnosis.
miRNAs Biogenesis
miRNAs are naturally occurring small single stranded non-coding RNAs that mediate gene expression 
at the post-transcriptional and translational level in both plants and animals (Ambros, 2004; Bartel, 
2004). The total numbers of identiﬁ  ed miRNAs are still increasing and the same is true for their key 
regulatory functions (Ruby et al. 2006).
The ﬁ  rst miRNA, lin-4, was initially discovered over a decade ago in Caenorhabditis elegans and 
controls the timing and progression of the nematode life cycle (Feinbaum & Ambros, 1999; Lee et al. 
1993; Reinhart et al. 2000). However, the importance of this research was not fully appreciated until 
recently with the discoveries of hundreds of miRNAs in worm, ﬂ  y and mammalian genomes (Berezikov 
et al. 2005; Brennecke et al. 2003; Lagos-Quintana et al. 2001; Lagos-Quintana et al. 2003). Many 
miRNAs are evolutionarily conserved further implying that these miRNAs are involved with essential 
biological processes such as development (Berezikov et al. 2005; Sempere et al. 2003).
Brieﬂ  y, miRNAs are derived from endogenous genes that are initially transcribed as large RNA 
transcripts that are capped and polyadenylated. RNA polymerase II has been shown to be involved in 
their transcription in the nucleus to form large pre-miRNA transcripts (Basyuk et al. 2003; Cai et al. 
2004). miRNAs are then further processed to become mature miRNAs through a complicated process. 
This involves a large protein complex, which includes RNase III Drosha and its cofactor Pasha (Denli 
et al. 2004; Gregory et al. 2004; Lee et al. 2003). Large miRNA transcripts are processed by Drosha 
into 70 nt hairpin pre-miRNAs that are transported by exportin-5 to the cytoplasm (Bohnsack et al. 
2004). Mature miRNAs, 18–27 nucleotides in length, are processed from pre-miRNAs by another 
RNaseIII nuclease Dicer (Lee et al. 2002). More details about miRNA biogenesis were described in 
other two comprehensive reviews (Esquela-Kerscher & Slack, 2006; Yanaihara et al. 2006).
Bioinformatics Tools for Investigating miRNA Biology
Two approaches have been applied to identify miRNA genes on a large scale. They are direct biochem-
ical cloning and computational approaches (Bentwich et al. 2005; Berezikov et al. 2005). It has been 
estimated that there are as many as 1,000 miRNAs in the human genome. Several databases have been 246
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created for storing and cataloging miRNA 
sequences as they are identiﬁ  ed including miRBase 
and MicroRNAdb (Grifﬁ  ths-Jones et al. 2006). 
After miRNAs have been identiﬁ  ed, the next goal 
is to identify and experimentally validate their 
mRNA targets. A particular miRNA can interact 
with several hundred mRNA targets via perfect or 
imperfect base-pairing primarily in the 3’-UTR 
(Schwarz et al. 2003). Since direct experimental 
methods for discovering miRNA targets are 
lacking, a large number of target prediction algo-
rithms have been developed. In plants, miRNA 
targets are computationally identiﬁ  ed through the 
extensive complementarity between miRNAs and 
their corresponding targets. However, computa-
tional identiﬁ  cation of miRNA targets in mamma-
lian miRNAs is considerably more difﬁ  cult because 
most animal miRNAs only partially hybridize to 
their mRNA targets.
miRNA target prediction programs typically 
rely on a combination of speciﬁ  c-base pairing rules 
and conservational analysis to score possible 
3’-UTR recognition sites and enumerate putative 
gene targets. Predictions based solely on base-
pairing rules yield a large number of false-positive 
hits. The number of false-positive hits, as estimated 
by random shufﬂ  ing of miRNA sequences, can be 
greatly reduced however by limiting hits to only 
those conserved in other organisms (John et al. 
2004; Lewis et al. 2003). By systematically varying 
selected miRNA sequences and testing for their 
ability to repress a given target, several rules have 
been established for miRNA:target binding (Bren-
necke et al. 2005; Doench & Sharp, 2004; Kiria-
kidou et al. 2004). Valid miRNA targets must either 
1) share a high level of sequence complimentarity 
with positions 2–8 of the 5’ side of the miRNA or 
2) share a low level of sequence complimentarity 
in the 5’ side of the miRNA in addition to a high 
degree of similarity in the 3’ side (Rajewsky, 2006). 
It is thought that a minimum 4 nucleotides on the 
5’ side must match perfectly and that G:U wobble 
pairs, despite their energetic stability, serve to 
disrupt miRNA targeting (Brennecke et al. 2005), 
although recently this idea has been challenged 
(Didiano & Hobert, 2006). Most current programs 
have overemphasized predictions based on 
the first category and have largely omitted 
miRNA targets that are stabilized by high 3’ end 
complementarity.
As base-pairing rules have been elucidated 
experimentally and with the availability of more 
genomic sequences, the original prediction 
programs such as TargetScan (Lewis et al. 2003), 
miRanda (Enright et al. 2003), and RNAhybrid 
(Rehmsmeier et al. 2004) have recently been 
reﬁ  ned and replaced by new versions such as 
TargetScanS (Lewis et al. 2005), PicTar (Grun 
et al. 2005; Krek et al. 2005), and miRanda (John 
et al. 2004). TargetScanS computes seed binding 
sites based on perfect complementarity of a 
7 nucleotide region conserved across ﬁ  ve organ-
isms (chicken, mouse, chimp, human and dog) 
between bases 2–8 on the 5’ end of the miRNA. 
miRanda uses a modiﬁ  ed approach to ﬁ  nd miRNA 
binding sites which do not require perfect seed 
binding (Enright et al. 2003; John et al. 2004). In 
their approach, a dynamic programming algorithm 
weighted to favor 5’ complementarity is used to 
enumerate initial target sites, which removes the 
requirement for perfect binding on the 5’ side. The 
lowest energy alignment of the miRNA and target 
is computed using the Vienna package (Wuchty 
et al. 1999). A conservation cut-off is then 
employed to choose target sites well-conserved 
between other vertebrates and/or mammals. Stark 
et al. (Stark et al. 2005; Stark et al. 2003), uses a 
very similar approach which relies on HMMer 
(Eddy, 1998) to produce the initial alignments. 
Kiriakidou et al. (Kiriakidou et al. 2004) also used 
a similar approach named “DIANA-microT” to 
predict miRNA-recognition elements, but used 
modiﬁ  ed initial base-pairing rules that focus on the 
sizes of allowable bulges in initial seeds. Another 
commonly used algorithm is PicTar, which starts 
by looking for perfect seed binding of 7 nucleotides 
in the 5’ end starting at either the ﬁ  rst or second 
position (Krek et al. 2005). The free energy of 
miRNA:target binding is then computed for seeds 
with imperfect matches. To delineate a list of 
predicted target sites, energy thresholds are 
imposed and then a maximum likelihood score is 
computed based on conservation across multiple 
organisms.
While conservation has been a primary aspect 
used to ﬁ  lter hits in most target prediction algo-
rithms, it is important to realize that not all target 
sites are necessarily conserved. Programs such as 
the newly developed microTar, which relies on 
base pairing rules and binding free energy calcula-
tions, have moved away from reliance on conser-
vation (Thadani & Tammi, 2006). Other recent 
variations (Yan et al. 2007), including miTarget 
(Kim et al. 2006), utilize a support vector machine 247
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(SVM) classiﬁ  er, which uses features such as the 
thermodynamic free energy of binding between 
the miRNA and possible target site, base compli-
mentarity at specific positions and structural 
features such as mismatches and bulges as input. 
This approach is limited, however, by the lack of 
availability of experimentally validated targets for 
classiﬁ  er training.
miRNA target prediction tools have been 
applied in a variety of organisms including 
C. Elegans, Drosophila, zebraﬁ  sh, and humans and 
have served two primary functions. The ﬁ  rst is to 
allow researchers to narrow down the list of poten-
tial gene targets for experimental conﬁ  rmation and 
validation when searching for a particular miRNA 
target. The second is to predict the number of genes 
regulated by miRNAs and various global trends in 
miRNA regulation. For instance these algorithms 
predict between 10% and 30% of all genes that are 
regulated by miRNAs (Grun et al. 2005; John et al. 
2006; Lewis et al. 2005).
We have only touched on a fraction of the total 
number of miRNA target prediction tools currently 
available, although most use algorithms similar in 
nature to the ones discussed above. Recently, 
Sethupathy et al. examined how a researcher 
should go about ﬁ  nding a list of predicted miRNA 
targets given the large number of available software 
packages (Sethupathy et al. 2006a; Sethupathy 
et al. 2006b). It is clear from this work that a variety 
of tools should be employed to elucidate targets as 
no one tool can comprehensively elucidate all 
possible targets. Secondly, it is important to realize 
that ideally one would compare algorithms based 
on metrics for sensitivity and selectivity, however 
the limited number of conﬁ  rmed miRNA targets 
(i.e. true positives) and the even more limited 
number of miRNAs known to not interact with a 
target gene (i.e. true negatives), prevent detailed 
evaluation. In addition, most of the few experi-
mentally determined targets come from studies 
validating target predictions and thus do not provide 
unbiased training or evaluation datasets. To over-
come these limitations, most algorithms to date have 
used randomized miRNA sequences as the primary 
method to validate sensitivity. The estimated false 
positive rates of these predictive algorithms range 
from 20–30% although the use of randomized 
sequence in general tends to underestimate the 
number of false positive hits (John et al. 2004). 
Another problem in comparing predictions from 
different algorithms is that there is substantial 
variation in the input 3’-UTR sequences since anno-
tated full-length cDNA datasets differ and can ignore 
tissue-speciﬁ  c isoforms (Rajewsky, 2006).
The current most commonly used approach for 
experimentally validating miRNA targets is to use 
a luciferase reporter construct by cloning the 
predicted binding site sequence of the miRNA into 
the 3’-UTR region (Reinhart et al. 2000; Wang et al. 
2004). The miRNA is then transfected into a cell 
line containing the luciferase reporter to access the 
effect of the miRNA on luciferase expression 
(Davis et al. 2006). However, this approach is not 
high-throughput and the miRNA binding sequence 
is taken out of the context of the target transcript. 
Because miRNAs can block translation by either 
direct binding at the 3’-UTR or degrading target 
mRNAs, conventional microarray based approaches 
only identify portions of the miRNA targets 
(Wang & Wang, 2006). Innovative high-throughput 
approaches must still be developed to systemati-
cally validate degraded and non-degraded miRNA 
targets. Several databases have recently been estab-
lished, including Argonaute (Shahi et al. 2006), 
TarBase (Megraw et al. 2007; Sethupathy et al. 
2006a), miRBase (Griffiths-Jones, 2006) and 
miRNAMAP (Hsu et al. 2006), which allow 
researchers to submit miRNA target data and 
experimental details into a public database. As 
larger numbers of validated miRNA targets (true 
positives) and validated non-targets (true negatives) 
become available, it will greatly aid the reﬁ  nement 
and evaluation of target prediction software.
Currently, limited information is available on 
how miRNAs are regulated at the transcriptional 
level. In order to learn more about what sequences 
may cis-regulate the transcription of miRNA precur-
sors, JASPAR (Sandelin et al. 2004) and TRANSFAC 
(Matys et al. 2003) have been used to search for 
transcription factor binding sites in the promoter 
regions of miRNAs (Lee et al. 2007; Xi et al. 2006a). 
We expect that with the increasing realization of the 
importance of miRNA regulation, that the search 
for factors that inﬂ  uence miRNA production through 
both experimental and computational techniques 
will be an active ﬁ  eld of study.
miRNAs and Cancer
Cancer is a genetic based disease and genetic 
defects in tumor suppressor genes and the activation 
of oncogenes are major contributors to the disease 
pathogenesis. In the past, most studies have 248
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focused on protein coding genes and their regula-
tion at the transcriptional level. Over the past few 
years, however, post-transcriptional and transla-
tional controls regulated by naturally occurring 
non-coding RNAs have emerged as an interesting 
ﬁ  eld of research. Translational control mediated 
by miRNAs provides the cell with a more precise, 
immediate, and energy-efﬁ  cient way of controlling 
the expression of proteins since it can induce rapid 
changes in protein synthesis without the need for 
transcriptional activation and subsequent mRNA 
processing steps. In addition, translational control 
provides the cell with greater flexibility in 
responding to various cytotoxic stresses. As 
mentioned earlier, the main function of miRNAs is 
to repress gene expression at the translational level 
by binding to the 3’-UTR of the messenger RNA. 
Although the exact function of most of the newly 
discovered miRNAs and siRNAs are just emerging, 
their ability to regulate cell proliferation and cell 
death has been recently shown (Chan et al. 2005).
The recent explosion of miRNA research and 
discovery further underscores the importance of 
these regulatory molecules in many key biological 
processes, such as development, cellular differen-
tiation, cell cycle control and apoptosis (Carmell 
et al. 2002; Karube et al. 2005; Lee et al. 2005; 
Takamizawa et al. 2004). There is enough evidence 
to show that miRNAs are involved in human cancer 
(Costinean et al. 2006; Saito et al. 2006). It was 
suggested previously that miRNAs assert their 
function as oncogenes or tumor suppressor genes 
via several potential mechanisms. If a particular 
miRNA targets key tumor suppressor genes, it is 
supposed to be an oncogene; but, if a miRNA 
targets an oncogene, it might be viewed as a tumor 
suppressor gene. However, the matter may be far 
more complicated than this simple view because 
one particular miRNA can mediate the expression 
of up to several hundred mRNAs. We speculate 
that to a large extent, the function of miRNAs is 
to ﬁ  ne tune gene expression in response to acute 
changes in growth conditions rather than as a 
traditional tumor suppressor or oncogene by 
deﬁ  nition.
The ﬁ  rst evidence that miRNAs may function 
as tumor suppressor genes came from a recent 
study by Calin et al. that showed that patients with 
B-cell chronic lymphocytic leukemia (CLL) have 
frequent deletions or down regulation of two 
miRNA genes, hsa-miR-15a and hsa-miR-16-1 
(Calin et al. 2002). Cimmino et al. showed that an 
anti-apoptotic gene BCL2, was negatively regu-
lated by hsa-miR-15a and hsa-miR-16-1 (Cimmino 
et al. 2005). This suggests that deletion or down 
regulation of hsa-miR-15a and hsa-miR-16-1 
results in an elevated level of BCL2 to promote 
leukaemogenesis and lymphomagenesis in haema-
topoietic cells. However, Borkhardt et al. reported 
recently that among 69 B-cell cases with 13q dele-
tion, none of them showed mutations in hsa-miR-
15a and hsa-miR-16-1 (Borkhardt et al. 2006). 
Fulci et al. also reported that the down regulation 
of hsa-miR-15a and hsa-miR-16-1 only occurred 
in 11% of 56 cases of B-cell CLL (Fulci et al. 2007). 
In another report, Linsley et al. demonstrated that 
hsa-miR-15a and hsa-miR-16-1 do not behave as 
classical tumor suppressor genes and most impor-
tantly, they do not regulate BCL2 expression at both 
mRNA and protein level (Linsley et al. 2007). 
These results suggest that our notion of miRNAs 
can not be simply classiﬁ  ed as traditional tumor 
suppressor genes or oncogenes and more studies 
are clearly needed to address this issue.
He et al. and O’Donnell et al. provide a direct 
relationship between miRNA expression, Myc and 
cancer (He et al. 2005; O’Donnell et al. 2005). 
They discovered that the expression of the mir-
17-92 cluster located in the 13q31 locus (hsa-miR-
17-5p, hsa-miR-17-3p, hsa-miR-18a, hsa-miR-19a, 
hsa-miR-20a, hsa-miR-19b, and hsa-miR-92-1) 
was ampliﬁ  ed in diffuse large B-cell lymphoma. 
In particular, the expression of the mir-17-92 
cluster was overexpressed in 65% of B-cell 
lymphoma samples. Myc induces the expression 
of the mir-17-92 cluster, and chromatin immuno-
precipitation experiments revealed that Myc 
interacts within the ﬁ  rst intron of the mir-17-92 
pre-miRNA transcript.
miRNAs are also involved in solid tumors such 
as lung cancer, breast cancer and colorectal cancer 
(CRC) (Iorio et al. 2005; Karube et al. 2005; 
Michael et al. 2003). In this review, we will focus 
on the roles of miRNAs in colorectal cancer and 
related issues in miRNA target discovery and vali-
dation. A tremendous amount of progress has been 
made in the past by focusing on the mechanism of 
transcriptional regulation; however, until recently, 
gene expression regulated at the translational level 
still remained to be investigated in detail, in 
particular translational control mediated by 
miRNAs in colorectal cancer.
In 2003, Michael et al. ﬁ  rst reported the reduced 
accumulation of speciﬁ  c miRNAs in colorectal 249
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cancer (Michael et al. 2003). In this study, small 
RNA fragments isolated from a Duke’s stage B 
colonic adenocarcinoma and matched normal 
mucosa were cloned. Among over 250 clones, a 
number of miRNAs were identiﬁ  ed to be deregu-
lated such as hsa-miR-143, hsa-miR-145, hsa-
miR-21, hsa-miR-200c and let-7a. Hsa-miR-143 
and hsa-miR-145 had decreased expression in both 
tumors and precancerous tissues compared to 
normal samples using Northern blot analysis. 
Several cancer cell lines including colorectal 
adenocarcinoma (CaCo-2 and LIM1863 organ-
oids), breast carcinoma (MCF-7 and T47-D), 
prostate carcinoma (LNCaP), chronic myelogenous 
leukemia (MEG-01) and cervical carcinoma 
(HeLa) also were found to have decreased expres-
sion levels of hsa-miR-143 and hsa-miR-145. 
Down-regulation of hsa-miR-145 has also been 
reported in lung and breast cancer (Iorio et al. 
2005; Yanaihara et al. 2006).
Based on target prediction with miRBase, 
hsa-miR-143 and hsa-miR-145 may suppress genes 
involved in signal transduction, and oncogenesis 
such as RAF1 kinase, G-protein γ7, tumor-
suppressing subfragment candidate 1 and sodium 
and potassium-dependent ATPase a subunit 
(ATP1A1). Akao et al. independently reported that 
the hsa-miR-143 and hsa-miR-145 expression 
levels were extremely reduced in colon cancer cell 
lines DLD-1 and SW480 (Akao et al. 2006b); 
Bandres et al. reported that the expression of 
hsa-miR-145 was not detected in any of 15 tested 
CRC cell lines, including DLD-1 and SW480, 
and was down-regulated in all tumor samples tested 
(Bandres et al. 2006). Similar results were obtained 
by Cummins et al. in CRC (Cummins et al. 2006); 
however, most of the samples used in these studies 
were colon cancer cell lines and the clinical sample 
sizes were relatively small. Nakajima et al. claimed 
that the expression levels of hsa-miR-143 and hsa-
miR-145 were not signiﬁ  cantly different in 46 
Japanese clinical colorectal tumor samples 
compared to their corresponding normal samples 
(Nakajima et al. 2006). These contradictory results 
may reﬂ  ect that the expression of certain miRNAs 
in cell culture model may differ from in vivo tumor 
specimens.
Factors involved in the transcriptional regula-
tion of miRNAs are still not thoroughly investi-
gated. O’Donnell et al. had also shown that the 
transcription factor c-Myc regulates a number of 
miRNAs, and that two of these miRNAs, miR-17-5p 
and miR-20a, in turn regulated E2F expression. 
c-Myc is a helix-loop-helix leucine zipper tran-
scription factor that regulates an estimated 10–15% 
of genes in the human genome (O’Donnell et al. 
2005). We hypothesize that p53 may similarly 
mediate the expression of certain miRNAs due to 
its function as a transcription factor (Xi et al. 
2006a). P53 may affect the gene expression of 
other cellular mRNA at the translational level either 
via its mediated miRNAs or due to its own RNA-
binding functionality (Fu et al. 1996).
P53 is one of the most frequently altered tumor 
suppressor genes in colon cancer due to its muta-
tions and deletions. In order to explore the 
potential relationship between the transcription 
factor p53 and miRNA expression in a colon 
cancer–related context, the human HCT-116 
(wt-p53) and HCT-116 (null-p53) colon cancer 
cell lines were explored as model systems to 
investigate the role of p53 on the expression of 
miRNAs. Our study indicated that the expression 
levels of a number of miRNAs were regulated by 
wt-p53 (Xi et al. 2006a). Hsa-miR-26, an example 
of these miRNAs, was up-regulated when p53 
was knocked-down, but abolished and down-
regulated through overexpression of p53 via 
translational regulation. Global sequence analysis 
using the TFBS and TRANSFAC transcription 
factor binding site databases revealed that more 
than 46% of the 326 miRNA putative promoters 
contain potential p53-binding sites, suggesting that 
some of these miRNAs were potentially regulated 
directly by wt-p53 (Lenhard & Wasserman, 
2002).
The in vivo signiﬁ  cance of deregulated miRNAs 
in relation to chemosensitivity was examined in a 
separate study (Xi et al. 2006b). The expression 
levels of ten miRNAs (hsa-miR-30a-5p, hsa-miR-
181b, hsa-let-7g, hsa-miR-26a, let-7b, hsa-miR-
15b, hsa-miR-27a, hsa-miR-200c, hsa-miR-191, 
and hsa-miR-30c) were investigated to evaluate 
their clinical relevance in colorectal cancer. 24 
normal and paired colorectal cancer specimens were 
selected as a model for this investigation. These ten 
miRNAs were selected due to their high expression 
levels in tumors displaying p53 deletion, their rela-
tionship with p53 and their predicted target 
mRNAs. Some of these miRNAs, including hsa-
miR-15b, hsa-miR-181b, hsa-miR-200c and has-
miR-191, were found to function as oncogenes due 
to their overexpression in tumors. Sequence anal-
ysis revealed that hsa-miR-181b and hsa-miR-200c 250
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expression levels were strongly associated with the 
mutation status of the p53 in tumor. Most impor-
tantly, based on the current clinical follow-up 
information, the patients with lower hsa-miR-200c 
expression had an average survival period 12 
months longer than patients with higher hsa-miR-
200c expression. This is the ﬁ  rst report to indicate 
that miRNAs are a potential novel prognostic factor 
for the survival of patients with colorectal cancer.
Nakajima et al. (2006) also found let-7g, hsa-
miR-181b and hsa-miR-200c were overexpressed 
using archived paraffin-embedded clinical 
colorectal cancer samples from Japan compared to 
corresponding normal tissues. Let-7g and hsa-miR-
181b were strongly associated with patients’ 
response to S-1 treatment, a fourth generation 5-FU 
based oral drug developed to improve drug efﬁ  -
cacy, reduced side-effects and improved quality of 
life (Nakajima et al. 2006).
Let-7a attracts much attention because it has 
been functionally proven to repress RAS and/or 
c-Myc expression at the translational level (Johnson 
et al. 2005). The involvement of RAS and c-Myc 
in many cancers has been established. Recently, 
after Takamizawa et al. found reduced let-7a 
expression levels in lung cancer (Takamizawa et al. 
2004), Akao et al. stated that let-7a could function 
as a potential tumor suppressor in human colon 
cancer cells (Akao et al. 2006a). They examined 
let-7a expression in six colon cancer patient 
samples and in human colon cancer cell lines 
DLD-1, SW480, and COLO201 using quantitative 
RT-PCR. Let-7a was signiﬁ  cantly decreased in 2 
of the 6 patients tested compared to the adjacent 
non-cancerous tissue. DLD-1 showed the lowest 
expression level among three colon cancer cell 
lines. They also found that up-regulation of let-7a 
though exogenous transfection could suppress the 
DLD-1 cell growth based on translational repres-
sion of RAS and c-Myc.
A recent study examined miRNA expression in 
ﬁ  fteen colon cancer cell lines, one normal colon 
cell line and twelve-matched-pair tumor and non-
tumor tissues using real time qRT-PCR (Bandres 
et al. 2006). In this report, among 156 miRNAs 
analyzed only thirteen, including hsa-miR-21, hsa-
miR-133b and hsa-miR-145, were found to be 
significantly decreased in both cell lines and 
clinical samples. Expression of hsa-miR-31 was 
found to be correlated with tumor staging. Let-7g 
and hsa-miR-200c were overexpressed in colon 
cancer cell lines versus normal cells. However, in 
this study, let-7a was used as an endogenous 
control for quantitative qRT-PCR analysis, but, as 
described above, let-7a was later shown to be 
deregulated in colorectal cancer.
Cummins et al. developed a novel technology 
named miRNA serial analysis of gene expression 
(miRAGE) and analyzed 273,966 cDNA tags 
obtained from human colorectal cancers and 
matched normal colonic mucosae (Cummins et al. 
2006). A total of 200 known mature miRNAs, 133 
novel miRNA candidates, and 112 previously 
uncharacterized miRNA forms were identiﬁ  ed. 
Twenty miRNAs including hsa-miR-191 and hsa-
miR-21 were overexpressed and thirty-two 
miRNAs including hsa-miR-143, hsa-miR-145 and 
let-7a had reduced expression in tumors.
While, the above studies indicate that some 
miRNAs could be potential biomarkers in 
colorectal cancer, the direct involvement of 
miRNAs in colorectal cancer carcinogenesis, prog-
nosis and chemosensitivity remain to be further 
investigated.
Summary and Future Perspectives
There are many challenges, and there is much 
excitement in the ﬁ  eld of miRNA research. We are 
just starting to uncover the huge potential of 
miRNAs as novel biomarkers and therapeutic 
targets for medicine. Computational prediction of 
miRNA targets is an active ﬁ  eld of research, which 
is greatly in need of new technologies to facilitate 
experimental validation. The impact of miRNAs 
on biology and disease largely remains to be 
explored especially in the ﬁ  eld of cancer research. 
Because one particular miRNA can mediate trans-
lational efﬁ  ciency of several hundred mRNAs 
(including both oncogenes and tumor suppressor 
genes), we speculate that the function of most 
miRNAs is to ﬁ  ne tune gene expression to provide 
cells more ﬂ  exibility and the ability to quickly 
respond to environmental changes. Obviously, if 
one particular miRNA is deleted, mutated, or 
highly overexpressed, then serious consequences 
will likely occur that lead to disease. Due to the 
relative small number of miRNAs and their rela-
tively high stability, miRNAs may better serve as 
biomarkers than mRNAs. Additional innovative 
tools for studying miRNAs targets and functions 
need to be developed. We also believe that “systems 251
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biology” approaches that combine a variety of data 
sources such as gene expression and miRNA 
expression and targeting will help us to better 
understand miRNA biology in cancer and other 
types of disease.
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